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Abstract
Vitamin D has been associated with decreased risk of several cancers. In experimental studies,
vitamin D has been shown to inhibit cell proliferation and induce differentiation and apoptosis in
normal and malignant breast cells. Using a population-based case-control study on Long Island,
New York, we examined the association of breast cancer with plasma 25-hydroxyvitamin D (25-
OHD) levels, a measure of vitamin D body stores. In-person interviews and blood specimens were
obtained from 1,026 incident breast cancer cases diagnosed in 1996 to 1997 and 1,075 population-
based controls. Plasma 25-OHD was measured in batched, archived specimens by Diasorin RIA.
The mean (SD) plasma 25-OHD concentration was 27.1 (13.0) and 29.7 (15.1) ng/mL in the cases
and controls, respectively (P < 0.0001). Plasma 25-OHD was inversely associated with breast
cancer risk in a concentration-dependent fashion (Ptrend = 0.002). Compared with women with
vitamin D deficiency (25-OHD, <20 ng/mL), levels above 40 ng/mL were associated with
decreased breast cancer risk (odds ratio, 0.56; 95% confidence interval, 0.41–0.78). The reduction
in risk was greater among postmenopausal women (odds ratio, 0.46; 95% confidence interval,
0.09–0.83), and the effect did not vary according to tumor hormone receptor status. In summary,
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these results add to a growing body of evidence that adequate vitamin D stores may prevent breast
cancer development. Whereas circulating 25-OHD levels of >32 ng/mL are associated with
normal bone mineral metabolism, our data suggest that the optimal level for breast cancer
prevention is ≥40 ng/mL. Well-designed clinical trials are urgently needed to determine whether
vitamin D supplementation is effective for breast cancer chemoprevention.
Breast cancer is the most common cancer among women in the United States. Due to the
magnitude of this disease, considerable research effort has been directed toward identifying
breast cancer risk factors to target for prevention. However, relatively few modifiable
lifestyle and environmental factors have been associated with reduced breast cancer risk.
Chemoprevention refers to altering the carcinogenesis process with a drug intervention. The
antiestrogens, tamoxifen and raloxifene, are the only drugs that have been approved by the
U.S. Food and Drug Administration for breast cancer prevention in high-risk populations.
Due to serious toxicities associated with these agents, namely endometrial cancer and
thromboembolic disease, they have not gained widespread acceptance in the primary
prevention setting. In addition, these antiestrogens do not lower the incidence of more
aggressive estrogen receptor (ER)-negative breast cancers, which account for about one
third of all breast tumors and are associated with a poorer prognosis compared with ER-
positive cancer.
Vitamin D is a fat-soluble vitamin that regulates calcium and bone homeostasis but also has
diverse biological effects relevant to carcinogenesis. Modest amounts of vitamin D come
from dietary sources such as fortified dairy products and cereals, fatty fish, and supplements.
However, the majority of vitamin D, up to 90%, is produced naturally in the body when
UVB light hits a precursor molecule in the skin. Vitamin D then undergoes a series of
hydroxylation steps in the liver to yield 25-hydroxyvitamin D (25-OHD), the major
circulating metabolite, and in the kidney to produce 1,25-dihydroxyvitamin D [1,25-
(OH)2D], the most biologically active form. 1,25-(OH)2D exerts its effects in tissues
traditionally linked with mineral metabolism, such as bone, kidney, and intestine, by binding
to the vitamin D receptor. In addition, extrarenal vitamin D activation occurs in diverse
target tissues, such as the colon, prostate, and breast, which express the activating enzyme
(1α-hydroxylase) and the vitamin D receptor, to locally regulate cell turnover (1,2).
Activated vitamin D exerts its antitumor effects via the vitamin D receptor to form a nuclear
receptor-ligand complex, which regulates the expression of target genes such as p21, p27, c-
fos, and c-myc (2).
Ecological studies have associated increased solar UVB irradiation with lower breast cancer
incidence and mortality (3–5). Numerous preclinical studies have shown that 1,25-(OH)2D
inhibits cell proliferation, induces differentiation and apoptosis, and has antiangiogenesis
effects in normal and malignant breast cells (6–9). Several epidemiologic studies evaluating
the association between vitamin D and breast cancer risk have yielded inconsistent results
(10). Some of these studies assessed the effects of dietary and supplemental intake of parent
vitamin D. However, endogenous production through sunlight exposure is the major source
of vitamin D in the body. Measurement of the circulating concentration of 25-OHD provides
an integrated measure of vitamin D from all sources—diet, supplements, and sunlight
exposure—and is considered the best indicator of vitamin D body stores (11,12).
The Long Island Breast Cancer Study Project was undertaken specifically to investigate
environmental factors associated with breast cancer risk (13). We used samples and data
previously collected in the Long Island Breast Cancer Study Project to examine the
hypothesis that higher plasma 25-OHD levels are associated with decreased breast cancer
risk.
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Subjects of the Long Island Breast Cancer Study Project are from a population-based case-
control study conducted on Long Island, New York (13). Breast cancer cases were
composed of women over age 20 y who were residents of Nassau and Suffolk counties,
spoke English, and were newly diagnosed with in situ or invasive breast cancer between
August 1, 1996 and July 31, 1997. For full details of case ascertainment, see the description
of the parent study (13). Population-based controls were identified by random digit dialing
for those under age 65 y, and rosters from the Health Care Financing Administration (now
called the Center for Medicare and Medicaid Services) for those age 65 y or older. Controls
were frequency matched to the expected age distribution of case women by 5-y age groups.
In-person interviews were completed for 82.1% of eligible cases (n = 1,508) and 62.8% of
eligible controls (n = 1,556). Of those who completed an interview, 73.1% of cases and
73.3% of controls donated a blood sample. Of those who donated a blood sample, we were
unable to perform plasma 25-OHD measurements in 6.9% of cases and 5.8% of controls,
mainly due to insufficient sample to complete the assay. Thus, our final sample size was
1,026 cases and 1,075 controls.
Measurement of plasma 25-OHD
Plasma samples were stored in aliquots at −80°C until measurement. For quantification of
25-OHD in plasma, we used the Diasorin RIA method. This assay measures two distinct
forms of 25-OHD: cutaneously derived vitamin D3 (cholecalciferol) and vitamin D2
(ergocalciferol) derived from supplements or fortified foods (14). Samples were analyzed
between September 2007 and December 2007 using a total of eight lots of the assay.
Interassay accuracy and precision for quality controls were +4% and 15% at 17 ng/mL,
respectively. At 48 ng/mL, interassay accuracy and precision were +7% and 18%, and at 57
ng/mL, these were +15% and 15%, respectively. Cases and controls were assayed in each
batch and laboratory personnel were blinded to case-control status.
Data collection
Exposure information comes from two sources—the parent study questionnaire, which was
administered by trained interviewers in the subject's home, and laboratory analyses using
blood samples to measure plasma 25-OHD concentration (13). As part of the structured
questionnaire,10 respondents were asked about their medical history, reproductive history,
family history of cancer, body size changes, dietary factors, recreational physical activities,
cigarette smoking and alcohol consumption, occupational and residential history, and
demographic characteristics (13).
Statistical methods
We assessed the association of plasma 25-OHD and breast cancer risk by means of logistic
regression with adjustment for potential confounders. First, a test for global significance was
conducted using the Wald χ2 test. Odds ratios (OR) and 95% confidence intervals (95% CI)
were calculated using plasma 25-OHD concentration both as a continuous variable (in 5 ng/
mL increments) and categorical variable divided into four categories (<20, 20–29, 30–39,
and ≥40 ng/mL). Vitamin D deficiency has been variably defined in the literature, but 25-
OHD levels above 20 to 32 ng/mL (50–80 nmol/L) are considered optimal for bone health
(15,16). In our analysis, we defined vitamin D deficiency as plasma 25-OHD of <20 ng/mL.
For simplicity and more model flexibility, we categorized by groupings of 10 ng/mL. This
categorization also closely corresponds to the classification into quartiles according to the
distribution in the controls.
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All models were adjusted for age at reference as a continuous variable, defined as age at
diagnosis for cases and age at identification for controls. We examined potential
confounding by the following covariates as continuous variables [age at menarche, age at
first pregnancy, parity, body mass index (BMI)] or categorical variables [race (White/non-
White), first-degree family history of breast cancer, history of benign breast disease,
menopausal status, ever use of hormone replacement therapy, physical activity (average
number of hours of recreational activity per week by quartile), and season of blood
collection (January-March, April-June, July-September, October-December)]. Tests for
linear trend were done using each category as an ordinal variable.
Effect modification by menopausal status was examined by including multiplicative
interaction terms in the logistic regression model (17). Menopausal status was based on self-
reported information collected during the baseline interview, including date of last menstrual
period and prior hysterectomy or bilateral oophorectomy. Postmenopausal status was
defined as last menstrual period at least 6 mo from the reference date or removal of both
ovaries. If a subject had a hysterectomy without removal of both ovaries before her last
menstrual period, menopausal status was initially classified as unknown and then
reclassified based on the subject's age at reference (13). Differences in risk estimates by
hormone receptor status were examined using polytomous logistic regression (17). These
models categorized the dependent variable into four groups based on ER and progesterone
receptor (PR) positivity, negativity, or unknown status: ER+ and/or PR+, ER−/PR−, ER/PR
unknown, and controls. We also examined the associations with the cases restricted to
women with invasive breast cancer and those who had not yet initiated chemotherapy by the
time of the blood collection.
All tests were two sided and considered to be statistically significant if P value was <0.05.
All statistical analyses were conducted using the SAS version 9.1 (SAS Institute).
Results
Baseline characteristics including demographic information and breast cancer risk factor
data for the cases and controls are shown in Table 1. The mean age of cases and controls
was 58.6 and 56.1 years, respectively. Over 90% of participants were White and about two-
thirds were postmenopausal. Of the 1,026 breast cancer cases, 846 (82%) were invasive and
180 (18%) were in situ. The mean plasma 25-OHD concentration was 27.1 and 29.7 ng/mL
in the cases and controls, respectively (P < 0.0001).
Vitamin D deficiency, defined as plasma 25-OHD of <20 ng/mL, was relatively common
among the controls (28%). Table 2 shows the prevalence of vitamin D deficiency among the
controls, based on factors known to influence circulating vita-min D levels. Rates of vitamin
D deficiency did not differ substantially by age. Non-Whites had twice the rate of Whites for
vitamin D deficiency. Increasing BMI was associated with a higher rate of vitamin D
deficiency. There was also significant seasonal variation in the prevalence of vitamin D
deficiency, with the highest rate seen during the late winter-early spring months and the
lowest rate during the late summer-early fall months.
Plasma 25-OHD concentration was inversely associated with breast cancer risk in a
concentration-dependent fashion (Ptrend = 0.002; Table 3). Compared with a reference group
with vitamin D deficiency, plasma 25-OHD of ≥40 ng/mL was associated with a 44%
reduction in breast cancer risk. We also analyzed plasma 25-OHD as a continuous variable
in the multivariate model and found a significant reduction in breast cancer risk per 5 ng/mL
increment in plasma 25-OHD.
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Multivariate-adjusted estimates based on menopausal status are presented in Table 4. We
observed a significant inverse association between plasma 25-OHD levels and breast cancer
risk among postmenopausal women but not premenopausal women (Pinteraction = 0.024).
For example, among postmenopausal women, plasma 25-OHD of ≥40 ng/mL was
associated with a significant 54% reduction in breast cancer risk (OR, 0.46; 95% CI, 0.09–
0.83) compared with those with vitamin D deficiency. In contrast, the modest 17% reduction
observed among premenopausal women was not statistically significant (OR, 0.83; 95% CI,
0.36–1.30).
The decrease in the risk of breast cancer associated with circulating vitamin D did not vary
based on hormone receptor status (Table 5). We observed a significant inverse association
between plasma 25-OHD and risk of breast cancer that were ER+ and/or PR+, ER−/PR−,
and ER/PR unknown. Compared with women who were vitamin D deficient, plasma 25-
OHD of ≥40 ng/mL was associated with a significant 45% reduction in risk of invasive
breast cancer (OR, 0.55; 95% CI, 0.39–0.77; Ptrend = 0.003), whereas the corresponding
37% decrease observed among women with in situ breast cancer was nonsignificant (OR,
0.63; 95% CI, 0.35–1.14; Ptrend = 0.087; data not shown).
The median difference between time of diagnosis and time of blood draw in the cases was
60 days. We evaluated the potential effects of chemotherapy on plasma 25-OHD levels by
excluding the 206 (20%) cases who had received chemotherapy before blood collection
from the analysis. Results were similar comparing the highest category (25-OHD, ≥40 ng/
mL) to the lowest category (25-OHD, <20 ng/mL) for all cases (OR, 0.56; 95% CI, 0.41–
0.78) and for cases who had not initiated chemotherapy before blood draw (OR, 0.55; 95%
CI, 0.39–0.78; Ptrend = 0.003; data not shown).
Discussion
In this large population-based case-control study, vitamin D status as measured by plasma
25-OHD levels was inversely associated with breast cancer risk in a concentration-
dependent fashion. Women with circulating 25-OHD above 40 ng/mL had approximately a
40% reduction in breast cancer risk compared with those who were vitamin D deficient. We
found that the risk reduction was more pronounced among postmenopausal women but was
similar for hormone receptor–positive and hormone receptor–negative tumors. These results
add to a growing body of literature supporting a protective effect of vitamin D on breast
cancer risk, particularly among postmenopausal women.
Several epidemiologic studies examining the association between dietary and supplemental
intake of vitamin D and breast cancer risk have yielded inconclusive results (10). However,
dietary intake of vitamin D is not a complete measure of vitamin D status and is subject to
inaccuracies in recall of dietary intake. Circulating 25-OHD correlates with exogenous
intake and endogenous production of vitamin D, is the substrate for conversion to 1,25-
(OH)2D in target tissues, and may be the limiting factor in 1,25-(OH)2D synthesis,
particularly in extrarenal tissues (18).
Several studies have examined the association between endogenous 25-OHD levels and
breast cancer risk (Table 6). Of two small hospital-based case-control studies, one found a
significant inverse association for 25-OHD and breast cancer risk (19), and the other study
found an inverse association for 1,25-(OH)2D but not 25-OHD (20). These studies were
limited by small sample sizes and the use of hospital-based controls. Our results are
consistent with the recently reported findings from a large population-based case-control
study from Germany (21), which showed that postmenopausal women with serum 25-OHD
concentrations of ≥75 nmol/L (≥30 ng/mL) had about a 70% reduction in breast cancer risk
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compared with those with <30 nmol/L (<12 ng/mL). Although statistically insignificant, an
inverse association between plasma 25-OHD and 1,25-(OH)2D and breast cancer risk was
observed in the case-control study nested in the Nurses' Health Study (22). Another
prospective study of postmenopausal women nested within the Prostate, Lung, Colorectal,
and Ovarian Cancer Screening Trial did not observe an association between circulating 25-
OHD or 1,25-(OH)2D and breast cancer risk (23). Variability in study results may be
partially explained by differences in the study populations and the assays used for 25-OHD
measurement. In addition, vitamin D seems to be more effective in combating cancer near
the time of detection (24,25), which may explain why studies based on 25-OHD levels from
stored sera several years before cancer diagnosis often do not find an association. All of the
published studies on endogenous 25-OHD concentrations in relation to breast cancer risk
have used single measurements of 25-OHD and do not take into account changes in vitamin
D levels over time.
Plasma 25-OHD is a useful biomarker for measuring an individual's recent exposure to
environmental sources of vitamin D but may not correlate with lifetime patterns of sun
exposure or dietary intake. However, the half-life of 25-OHD in the circulation is about 2
months and blood levels are fairly consistent over time (26,27). It is unclear whether plasma
25-OHD varies following a cancer diagnosis and during cancer treatments. After a breast
cancer diagnosis, dietary and behavioral changes such as decreased dietary intake of vitamin
D or sunlight exposure may occur, which may alter plasma 25-OHD levels. Results of a
large nested case-control study showed that higher prediagnostic plasma 25-OHD levels
were associated with a trend toward decreasing breast cancer risk (22). In addition, three
prospective cohort studies on dietary/supplemental intake of vitamin D and breast cancer
risk supported an inverse association (28–30), whereas one did not (31). However, no
studies to date have offered a comprehensive assessment of all sources of vitamin D in
relation to cancer risk at levels of vitamin D exposure that may be needed for breast cancer
prevention.
As for the effects of cancer treatments on plasma 25-OHD levels, a notable change in 25-
OHD concentration after chemotherapy was not observed in two studies (32,33) or in our
own study of premenopausal women undergoing adjuvant chemotherapy for early-stage
breast cancer (34). When we restricted our analysis to cases who had not received
chemotherapy before blood collection, our results did not change.
Calcium may also have anticancer properties. Vitamin D and calcium are metabolically
interrelated and highly correlated dietary factors that may influence breast cancer
development through a variety of mechanisms (31,35). A population-based case-control
study from Germany examined the independent and joint effects of dietary vitamin D and
calcium on premenopausal breast cancer risk (36). In this study, breast cancer risk was
inversely associated with vitamin D but not calcium intake (36).
Prior studies have suggested that the association between vitamin D and breast cancer risk
may be stronger for premenopausal women compared with postmenopausal women. One
cohort study found a reduced risk of breast cancer in association with vitamin D intake
among premenopausal women, but no reduction in breast cancer risk in postmenopausal
women (28). In the Women's Health Study, higher intake of vitamin D was moderately
associated with a lower risk of breast cancer among premenopausal women, but not post-
menopausal women (29). Similarly, the Cancer Prevention Study II Nutrition Cohort
observed no association of breast cancer with total vitamin D intake among postmenopausal
women (31). However, these studies did not include evaluation of circulating 25-OHD
levels. We observed a significant inverse association between plasma 25-OHD levels and
breast cancer risk among postmenopausal women but not premenopausal women. Our
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results may be due to the smaller sample size of the premenopausal group. Compared with
postmenopausal women with vitamin D deficiency, those with plasma 25-OHD levels of
≥40 ng/mL had about a 50% reduction in breast cancer risk. Our results are consistent with
the findings of Abbas et al. (21), which showed a protective effect of vitamin D for
postmenopausal breast cancer.
We found a significant inverse association of vitamin D levels with breast cancer regardless
of hormone receptor status. Recent data from the Nurses' Health Study suggested an inverse
association for ER−/PR−, but not ER+ and/or PR+ tumors (22). The Iowa Women's Health
Study also found a stronger protective effect of vitamin D supplement use among women
with breast cancers that were negative rather than positive for ER or PR status (30). Our
results suggest that vitamin D may have anticancer effects that are independent of the ER
pathway, and that targeting the vitamin D pathway may be a useful preventive strategy for
ER-negative, as well as ER-positive breast cancers.
Our study has several strengths, including the population-based sampling of controls, a large
sample size that allowed us to stratify the data by potential effect modifiers, and the direct
assessment of vitamin D status by an assay that measures both dietary sources of vitamin D
(ergocalciferol) and endogenous vitamin D (cholecalciferol) synthesized in the skin. Vitamin
D assays were completed in a short period of time by the same laboratory and were shown to
have high precision. Potential sources of bias in our retrospective case-control design
include subject selection and measurement error on plasma 25-OHD concentration. In terms
of subject selection, response rates were lower among controls compared with cases,
especially among women over the age of 75 years (13). Therefore, these results may not be
generalizable to older women. In addition, blood donors differed from those who did not
donate blood on a number of factors (13). However, all models included the frequency
matching factor age at reference, and adjustment for other known breast cancer risk factors
did not appreciably change the effect estimates, and were therefore not included in our final
models. Unlike questionnaire exposure data, measurement of circulating 25-OHD levels is
not subject to recall bias, although laboratory error is possible. However, this measurement
error in plasma 25-OHD is unlikely to differ by case-control status given that all laboratory
specimens were labeled with a random number (and cannot be linked back to the subject by
the laboratory personnel); thus, this potential source of error cannot explain the observed
associations between 25-OHD and breast cancer risk.
Clinical trials of vitamin D supplementation suggest a benefit in the prevention setting. In
the Women's Health Initiative, over 36,000 postmenopausal women were randomized to
1,000 mg of calcium carbonate and 400 IU of vitamin D3 or matching placebo for 7 years
(37). Although breast cancer incidence did not differ between the two groups, personal
supplementation with vitamin D (up to 1,000 IU per day) was allowed, which may have
dampened the ability to differentiate between the active and control arms. In a subgroup
analysis of women who did not report additional personal supplement use (n = 19,115),
there was a significant decrease in breast cancer incidence with calcium and vitamin D
compared with placebo (hazard ratio, 0.82; 95% CI, 0.70–0.97). Another intervention trial of
calcium and 1,100 IU of vitamin D3 daily for 4 years in postmenopausal women found a
60% reduction in overall cancer incidence compared with placebo (24). However, the
number of cancer events was small and the follow-up was only 4 years. In addition, neither
this trial nor the Women's Health Initiative can distinguish between the effects of calcium
and vitamin D.
In the United States, the Dietary Reference Intake of vitamin D is 200, 400, and 600 IU
daily for adults ages <50, 50 to 70, and >70 years, respectively (38). Oral daily intake of
1,000 IU of vitamin D increases circulating 25-OHD levels by about 10 ng/mL (39). Given
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the high prevalence of vitamin D deficiency in the general population, to raise plasma 25-
OHD levels above 40 ng/mL, the putative target level for breast cancer risk reduction,
women would have to consume about 4,000 IU daily, which exceeds the National Academy
of Sciences upper limit of 2,000 IU/day (38). In the time since this upper safety limit was set
in 1997, accumulating evidence in trials of healthy adults suggests that doses well above
those recommended currently are safe (40). However, controversy in this field remains.
In summary, our study adds to a growing body of evidence that adequate vitamin D stores
may prevent the development of breast cancer. The protective effect of vitamin D was
stronger among postmenopausal women, but was similar for hormone receptor–positive and
hormone receptor–negative tumors. These results represent an important public health
finding, as women with low circulating 25-OHD levels may benefit from vitamin D
supplementation for breast cancer risk reduction. Whereas circulating 25-OHD levels of >32
ng/mL are associated with normal mineral metabolism, data from our study and others (41)
suggest that the optimal level for breast cancer prevention is ≥40 ng/mL. Future studies
should include repeated measures of 25-OHD to determine whether changes over time are
linked to cancer risk. In addition, well-designed clinical trials are necessary to determine
whether vitamin D supplementation is effective for breast cancer chemoprevention.
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Table 1
Baseline characteristics of the subset of breast cancer cases and controls with plasma 25-OHD levels, Long
Island Breast Cancer Study Project (1996–1997)
Baseline Characteristics Cases (n = 1,026) Controls (n = 1,075)
Mean (SD)
Age (y) 58.6 (12.5) 56.1 (12.5)
Age at menarche (y) 12.6 (1.5) 12.5 (1.6)
Parity* 2.4 (1.6) 2.5 (1.6)
Age at first birth (y)* 25.4 (4.6) 25.1 (4.5)
BMI (kg/m2) 26.6 (5.6) 26.3 (5.8)




First-degree family history of breast cancer 18.5 13.8
History of benign breast disease 19.3 13.7
Ever breastfeeding 34.2 36.2
Ever hormone replacement therapy 29.7 27.5
*
Among parous women (n = 890 cases and 955 controls).













Crew et al. Page 12
Table 2
Prevalence of vitamin D deficiency (plasma 25-OHD, <20 ng/mL) by age, race, BMI, and season of blood
draw among controls
Characteristics among controls Vitamin D deficiency n (%) P*
Age, y
 <40 29 (29) 0.480
 40–50 92 (32)
 51–60 79 (27)
 61–70 58 (25)
 >70 44 (29)
Race
 White 262 (26) <0.001
 Non- White 40 (49)
BMI, kg/m2
 <25 121 (22) <0.001
 25–30 101 (32)
 >30 80 (37)
Season of blood draw
 Jan–Mar 99 (38) <0.001
 Apr–Jun 99 (34)
 July–Sept 26 (12)
 Oct–Dec 78 (26)
*
Based on X2 test.
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Table 4
Multivariate-adjusted ORs and 95% CIs for breast cancer risk by plasma 25-OHD levels (ng/mL) stratified by
menopausal status
Menopausal Status Cases Controls OR (95% CI)*
Premenopausal
 <20 98 117 1.00
 20–29 79 82 1.07 (0.65–1.49)
 30–39 101 98 1.20 (0.81–1.59)
 ≥40 48 67 0.83 (0.36–1.30)
P trend 0.821
As continuous variable per 5 ng/mL increment 326 364 0.97 (0.92–1.02)
Postmenopausal
 <20 232 173 1.00
 20–29 190 196 0.70 (0.41–0.99)
 30–39 180 183 0.70 (0.40–1.00)
 ≥40 74 113 0.46 (0.09–0.83)
P trend <0.001
As continuous variable per 5 ng/mL increment 676 665 0.92 (0.89–0.96)
*
Adjusted for age, race, BMI, and season of blood draw.
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Table 6
Endogenous 25-OHD levels and breast cancer risk
Study Study Design No. cases/controls Comparison* OR (95% CI)
Lowe et al., 2005 (19) Hospital-based case-control 179/179 25-OHD (ng/mL) <20 vs >60 5.83 (2.31–14.7)
Abbas et al., 2008 (21) Population-based case-control 1,394/1,365 25-OHD (ng/mL) ≥30 vs <12 0.31 (0.24–0.42)
Crew et al. Population-based case-control 1,026/1,075 25-OHD (ng/mL) ≥40 vs <20 0.56 (0.41–0.78)
Bertone-Johnson et al., 2005
(22) Nested case-control 701/724 25-OHD (ng/mL) ≥40 vs ≤20
† 0.73 (0.49–1.07)
Freedman et al., 2008 (23) Nested case-control 1,005/1,005 25-OHD (ng/mL) ≥33.7 vs <18.3 1.04 (0.75–1.45)
*
For circulating concentration of 25-OHD, 1 ng/mL = 2.5 nmol/L.
†
For this study, breast cancer risk was analyzed by quintiles of plasma 25-OHD. Quintile cut points differed in the three batches of plasma 25-
OHD measurements.
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